One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Kaposi Sarcoma Market

[ 英語タイトル ] Kaposi Sarcoma Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0089138
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 111
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Merck & Co., Inc.
- Celgene Corporation
- Eli Lilly and Company
- Navidea Biopharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb
- Pfizer Inc.

[Report Description]

The growing prevalence of the Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures as patients undergoing organ transplantations are more susceptible for Kaposi sarcoma, are the major factor attributing the growth of the Kaposi sarcoma market.

According to Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017, where 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Moreover, a promising number of pipeline studies, growing incidence of HIV-associated Kaposi sarcoma is also a major factor driving Kaposi sarcoma market.

However, a shortage in supply of drugs due to a wide demand-supply gap, lack of awareness about this type of cancer, high cost of the treatment, and diagnosis of Kaposi sarcoma will impede the growth of the market studied globally.

Key Market Trends

Highly Active Antiretroviral Therapy (HAART) Segment Holds a Significant Market Share

Kaposi sarcoma (KS) is a common cancer associated with the HIV infection and it is considered as an AIDS-defining condition by the US Centers for Disease Control Guidelines. Numerous advancements in the treatment of AIDS-related Kaposi sarcoma have been attained over the last few years, but the introduction of highly active antiretroviral therapy (HAART) has declined the incidences of AIDS-defining illnesses, including KS.

For individuals with Epidemic (AIDS-associated) Kaposi sarcoma, antiretroviral treatment for HIV/AIDS is generally used prior to any other therapies for treating the tumor and to reduce the symptoms. HAART might be given as individual therapy or in the combination with chemotherapy depending on the spread of the disease and the patient’s symptoms. Seldom, HAART might worsen the condition of the Kaposi sarcoma and the pre-existing infections which leads to a condition called immune reconstitution inflammatory syndrome (IRIS).

North America holds Largest Market Share in Global Kaposi Sarcoma Market

North America region holds a major market share in the Kaposi treatment market globally. Major factors contributing to this position are the increasing number of product approvals, the presence of many numbers of market players in the market, a high number of R&D initiatives undergoing the treatment and the diagnosis of the Kaposi sarcoma. Additionally, the increasing prevalence of Kaposi sarcoma and HIV is also bolstering the market growth in the region. For instance, According to the American Cancer Society's (ACS) publication, about 1 in 200 transplant recipients in the United States develops Kaposi sarcoma.

Competitive Landscape

Kaposi Sarcoma market has rapidly progressed over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. For instance, in May 2019, The USFDA granted breakthrough therapy designation to Celgene’s pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence of HIV-Associated Kaposi Sarcoma
4.2.2 Rising Number of Patients Undergoing Organ Transplantation Procedures
4.3 Market Restraints
4.3.1 High Cost Of The Treatment And Diagnosis Of Kaposi Sarcoma
4.3.2 Shortage In Supply Of Drugs Due To Wide Demand-Supply Gap
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Epidemic (AIDS-associated) Kaposi sarcoma
5.1.2 Classic (Mediterranean) Kaposi sarcoma
5.1.3 Endemic (African) Kaposi sarcoma
5.1.4 Latrogenic (transplant-related) Kaposi sarcoma
5.2 By Product
5.2.1 By Diagnostics
5.2.1.1 Biopsy
5.2.1.2 Bronchoscopy
5.2.1.3 Gastrointestinal endoscopy
5.2.1.4 Others
5.2.2 By Treatment
5.2.2.1 Highly Active Antiretroviral Therapy (HAART)
5.2.2.2 Radiation Therapy
5.2.2.3 Chemotherapy
5.2.2.4 Immunotherapy
5.2.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co., Inc.
6.1.2 Celgene Corporation
6.1.3 Eli Lilly and Company
6.1.4 Navidea Biopharmaceuticals, Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Bristol-Myers Squibb
6.1.7 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+